Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00347958 · ClinicalTrials.gov registry record · Phase 4
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
A Phase 4 study of Diphtheria and Tetanus, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 545
- Enrollment target
- 10
- Study locations
NCT00347958 is a Phase 4 study of Diphtheria and Tetanus that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 545 participants, below the 1,830-participant average among 15 other Diphtheria trials with a reported enrollment target (70% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT00347958, a Phase 4 study of Diphtheria and Tetanus, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 545 participants
- Enrollment target
- 10
- Study locations
Study Summary
Objectives: To provide safety data on revaccination with ADACEL® vaccine. To describe the immune response to tetanus, diphtheria, and pertussis antigens following revaccination with ADACEL® vaccine 4-5 years after first vaccination.
Conditions Studied
Interventions
- BIOLOGICAL Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Study Locations (10)
British Columbia
- - Coquitlam
- - Surrey
Quebec
- - Beauport
- - Montreal
Arkansas
- - Jonesboro
Louisiana
- - Bossier City
Ohio
- - University Heights
Pennsylvania
- - Pittsburgh
Manitoba
- - Winnipeg
Nova Scotia
- - Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00347958
The ClinicalTrials.gov registry entry for NCT00347958 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 545 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,830-participant average among 15 other Diphtheria trials with a reported enrollment target (70% lower). The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diphtheria appearing as the primary indexed condition, and to 1 intervention - of which Tetanus-diphtheria-acellular pertussis (Tdap) vaccine is the first listed.
NCT00347958 reports 10 study locations spanning 8 distinct geographic areas - top geographies include British Columbia, Quebec, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00347958 about?
NCT00347958 is a clinical study titled "Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine". Objectives: To provide safety data on revaccination with ADACEL® vaccine. To describe the immune response to tetanus, diphtheria, and pertussis antigens following revaccination with ADACEL® vaccine 4-5 years after first vaccination.
What is the current status of trial NCT00347958?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 545 participants. The study started on 2006-08. Estimated completion is 2008-10.
What conditions does trial NCT00347958 study?
This clinical trial studies the following conditions: Diphtheria, Tetanus, Pertussis.
What interventions are being tested in trial NCT00347958?
The interventions under investigation include: Tetanus-diphtheria-acellular pertussis (Tdap) vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00347958?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00347958 being conducted?
This trial has 10 study locations across Arkansas, Louisiana, Ohio, Pennsylvania, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diphtheria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PFAS Exposure and Immune Response to Vaccination in Adults
COMPLETED · Phase 4
-
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
COMPLETED · Phase 4
-
US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease
COMPLETED · Phase 4
-
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
COMPLETED · Phase 4
-
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
COMPLETED · Phase 4
-
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.